eRAPID: Online Symptom Reporting in Lung Cancer

  • Research type

    Research Study

  • Full title

    eRAPID: Electronic monitoring of patient-reported symptoms in patients with a diagnosis of thoracic cancer managed at Leeds Cancer Centre

  • IRAS ID

    270042

  • Contact name

    Galina Velikova

  • Contact email

    g.velikova@leeds.ac.uk

  • Sponsor organisation

    University of Leeds

  • Clinicaltrials.gov Identifier

    NCTO4324437

  • Duration of Study in the UK

    2 years, 6 months, 4 days

  • Research summary

    Background: Recent advances in systemic treatments in thoracic cancer have improved treatment options available and increasing numbers of patients are being cured or are in remission. Approaches to improve monitoring and documentation of adverse events (AEs) during treatment and follow-up use patient reported outcome measures (PROMS) where patients self-report symptoms which are made available to clinicians electronically within the hospital record.

    Aims: To systematically capture patient reported disease symptoms and adverse events in patients treated with systemic anti-cancer therapy (SACT) for thoracic cancer. We will assess feasibility, acceptability and utility of introducing an electronic pathway to monitor thoracic cancer during treatment and one year follow-up.

    Methods: An existing online patient symptom reporting system will be adapted and extended for use within systemic treatment and follow up for a minimum of one year for thoracic cancer.

    A prospective real world study will be conducted in Leeds Cancer Centre. Two patient cohorts will be compared: 1) weekly completion of symptom reports online from home; 2) report online in clinic before their appointment. Recruitment to cohort 1 or cohort 2 is determined by patient choice
    Consecutive patients who meet the recruitment criteria will be approached with approximately 100 patients expected to enrol. Cohort 1 patient will receive self-management advice or advice to contact the hospital depending on the severity of their symptom report when they make their weekly completion. Cohort 2 patients will be able to view self-management advice in clinic and discuss their results immediately after with their clinician.
    Clinical and patient outcomes will be collected, and interviews held with healthcare professionals and a sub-set of patients.
    Objectives
    • Develop an electronic care pathway for monitoring patients under treatment and during one year’s follow-up
    • Obtain data on clinical and patient feasibility and disease and treatment related symptoms of patients with a diagnosis on thoracic cancer undergoing systemic treatment

  • REC name

    East Midlands - Leicester South Research Ethics Committee

  • REC reference

    20/EM/0026

  • Date of REC Opinion

    6 Mar 2020

  • REC opinion

    Further Information Favourable Opinion